In contrast, the levels of mesenchymal biomarkers, such as N-cadherin, vimentin, fibronectin and SLUG, were reduced in melanoma cells after treatment with GSPs in a dose-dependent manner, as shown in Figure 5A. The gene discussed is CDH2; the disease is melanoma.